Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

Johnson & Johnson's ERLEADA Plus Hormone Therapy Improves Outcomes in High-Risk Prostate Cancer

Johnson & Johnson announced positive final analysis results from the Phase 3 PROTEUS study, demonstrating that ERLEADA (apalutamide) combined with hormone therapy significantly improved outcomes for patients with high-risk localized or locally advanced prostate cancer. Administered six months before and after surgery, the combination led to patients being nine times more likely to achieve pathologic complete response/minimal residual disease (8.9% vs. 1.0%) compared to hormone therapy alone. The treatment also reduced the risk of metastasis or death by 20% and extended the time to subsequent therapy to over six years. These findings were presented at ASCO 2026 and published in The New England Journal of Medicine.

• The PROTEUS study successfully met both dual primary endpoints. Apalutamide plus hormone therapy achieved an 8.9% pathologic complete response/minimal residual disease (pCR/MRD) rate, significantly higher than the 1.0% observed with hormone therapy alone (odds ratio [OR], 10.17; 95% confidence interval [CI], 5.27-19.64; p<0.0001). Furthermore, the combination demonstrated a statistically significant 20% reduction in the risk of metastasis or death (hazard ratio [HR], 0.80; 95% CI, 0.67-0.96; p=0.02), with five-year metastasis-free survival rates of 78.2% versus 73.5%, respectively.
• Beyond the primary endpoints, the combination therapy showed statistically significant and clinically relevant improvements across key secondary outcomes. Patients treated with apalutamide plus hormone therapy before and after surgery experienced a median time of more than six years (74.2 months) before requiring subsequent therapy, a substantial increase compared to approximately three and a half years (41.5 months) for hormone therapy alone (HR, 0.65; p<0.0001). Additional benefits included a 29% reduction in the risk of disease recurrence or death and improved time to distant metastasis.
• The safety profile of apalutamide plus hormone therapy was consistent with prior studies. The most frequently reported adverse events (AEs) in the apalutamide arm included hot flush (63.4%), urinary incontinence (50.2%), and erectile dysfunction (41.6%). Grade 3 or 4 AEs occurred in 39.6% of patients receiving the combination, compared to 31.0% in the hormone therapy alone group. Discontinuations due to AEs were 7.4% and 2.7%, respectively, with similar rates of death between arms, though deaths in the apalutamide arm were more often unrelated to prostate cancer.

Addressing the Unmet Need in High-Risk Localized Prostate Cancer

High-risk localized prostate cancer continues to present significant clinical challenges despite advances in treatment modalities. Patients in this category face elevated risks of treatment failure and mortality compared to those with lower-risk disease. Current therapeutic approaches reveal several critical limitations that impact long-term outcomes and patient prognosis.

• High treatment failure and mortality rates - High-risk prostate cancer patients remain the group with higher risk of treatment failure and mortality rates, despite available treatment approaches including surgery, radiotherapy, and hormonal therapy

• Frequent biochemical and clinical recurrence - A large number of patients experience biochemical recurrence after undergoing radiotherapy, or even clinical recurrence, leading to treatment failure

• Development of therapeutic resistance - Prostate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression, with some cases exhibiting aggressive phenotypes or developing resistance to therapeutic interventions

• Inconsistent risk classification systems - Various definitions are currently in use to describe high-risk prostate cancer, which creates challenges for patient counseling since predicted outcomes depend on which classification is applied to identify the patient's risk category

• Limited curability despite combination approaches - Despite available treatment options being more effective when used as combination therapy, prostate cancer remains incurable, particularly when locally advanced

• Challenges in comprehensive disease assessment - Patients with advanced prostate cancer require comprehensive evaluations to detect rare metastatic sites, such as the brain, to avoid missed diagnoses and ensure appropriate treatment planning

PROTEUS Study: Unpacking Apalutamide's Efficacy and Safety

Recent clinical trials have demonstrated significant advances in treatment approaches for high-risk localized and locally advanced prostate cancer, with several studies providing key insights into optimal therapeutic strategies. These investigations span various treatment modalities including hormone therapy combinations, radiation therapy approaches, and novel systemic interventions.

Perioperative Apalutamide: Shifting the Prostate Cancer Treatment Paradigm

Comparative effectiveness data for investigational therapies versus standard-of-care treatments in high-risk localized or locally advanced prostate cancer reveals mixed outcomes across different therapeutic approaches. Analysis of 143 phase 3 randomized controlled trials comprising 88,603 patients with advanced cancers (including prostate cancer) demonstrated that experimental drugs showed improved progression-free survival (HR 0.80; 95% CI 0.78-0.82) and overall survival (HR 0.87; 95% CI 0.85-0.89) compared to control groups, with 57% of trials meeting their primary endpoints. However, this improved efficacy came at the cost of increased toxicity, with experimental drugs showing higher rates of toxic deaths (OR 1.14; 95% CI 1.03-1.27), treatment discontinuation without progression (OR 1.64; 95% CI 1.56-1.71), and grade 3/4 adverse events compared to standard treatments.

Radiation therapy modality comparisons provide more specific insights for high-risk prostate cancer management. A comparative analysis of stereotactic ablative radiotherapy (SABR) boost versus magnetic resonance-guided high-dose-rate brachytherapy (HDR-BT) boost, both combined with 6-18 months of androgen deprivation therapy, demonstrated superior biochemical control with SABR. The SABR approach achieved 0% actuarial 5-year biochemical failure compared to 18.2% with HDR-BT boost (P = 0.005), with no significant differences in acute or late gastrointestinal or genitourinary toxicity between groups. Notably, all six patients with biochemical failure in the HDR-BT group subsequently developed metastatic disease.

In the bone health management arena for advanced disease, the RANK ligand inhibitor denosumab demonstrated superior efficacy in preventing skeletal-related events compared to the standard bisphosphonate zoledronic acid in patients with metastatic prostate cancer. While denosumab showed improved skeletal protection, this enhanced efficacy was associated with increased side effects, requiring careful risk-benefit assessment particularly given the limited life expectancy in this end-stage patient population. These findings underscore the evolving treatment paradigm where investigational approaches may offer clinical benefits but require thorough evaluation of their safety profiles against established standard-of-care options.

Apalutamide's Early Intervention Reshapes Prostate Cancer Strategy

The recent announcement regarding apalutamide's positive Phase 3 PROTEUS study results marks a pivotal moment in the evolving treatment landscape for prostate cancer. For years, androgen receptor (AR) inhibitors like apalutamide have been instrumental in managing advanced disease, notably in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), where they have significantly improved patient outcomes, including overall survival. This new data, however, pushes the utility of apalutamide into an even earlier stage: high-risk localized or locally advanced prostate cancer, administered both before and after surgery.

The implications are substantial. Achieving a nine-fold higher rate of pathologic complete response/minimal residual disease, alongside a 20% reduction in the risk of metastasis or death, suggests that early, aggressive intervention with AR-targeted therapy could fundamentally alter the disease trajectory. This positions apalutamide to become a new standard of care, offering an intensification strategy that could prevent progression and extend the time patients remain free from subsequent therapies. This expansion into a pre- and post-surgical setting significantly broadens the eligible patient population and reinforces the strategy of targeting AR signaling throughout the disease continuum.

However, this promising development also brings important considerations. While AR-targeted therapies are highly effective, prostate cancer is known to develop resistance over time, sometimes through AR bypass mechanisms or the emergence of more aggressive tumor phenotypes. Managing potential adverse events, such as rash or fractures, in a larger, earlier-stage patient population will also be critical for long-term adherence and quality of life. Furthermore, the competitive landscape of AR antagonists remains robust, necessitating ongoing evaluation of optimal sequencing and combination strategies to maximize patient benefit. As personalized medicine advances, identifying biomarkers to predict response and guide treatment selection will be paramount in fully realizing the potential of these early interventions.